Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Shionogi-ViiV

- PMLiVE

GSK tops pharma access to medicines table

But corruption and intellectual property issues in developing nations

- PMLiVE

GSK first to file IL-5 antagonist for asthma

Mepolizumab submitted as a treatment for severe eosinophilic asthma

- PMLiVE

NICE backs GSK drug for leukaemia

Arzerra on course for NHS use in blood cancer

- PMLiVE

Pfizer gets FDA nod for meningitis vaccine Trumenba

Ahead of Novartis’ rival drug Bexsero

- PMLiVE

EU boost for GSK’s Ebola vaccine research

And EMA says it' poised to assess possible vaccines or treatments

- PMLiVE

GSK to sell off part of its HIV venture ViiV Healthcare

And sets out new restructure programme as US Seretide sales hit

- PMLiVE

FDA votes to keep severe warning on Pfizer’s Chantix

Will not relax anti-smoking drug's side effect warning

- PMLiVE

Russian HIV vaccine heading for phase II trials

But trials could be affected by lack of funding

- PMLiVE

Pfizer’s palbociclib on track for early 2015 launch

Good news for the highly anticipated breast cancer drug

- PMLiVE

Pfizer reports progress with meningitis vaccine

Race to US market heats up

- PMLiVE

Novartis announces departures of three execs

Follows deals to sell divisions to GSK and Lilly

- PMLiVE

GSK unit takes new ofatumumab formulation into phase III

Studied in autoimmune disorder of the skin

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links